Makiko Fujii

Summary

Affiliation: Aichi Cancer Center
Country: Japan

Publications

  1. pmc Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade
    Makiko Fujii
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Cell Cycle 11:3373-9. 2012
  2. doi request reprint Exploration of a new drug that targets YAP
    Makiko Fujii
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi 464 8681, Japan
    J Biochem 152:209-11. 2012
  3. pmc TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth
    Makiko Fujii
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Chikusa ku, Nagoya 464 8681, Japan
    J Exp Med 209:479-94. 2012
  4. doi request reprint Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma
    Futoshi Ishiguro
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    J Thorac Oncol 7:890-9. 2012
  5. doi request reprint Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer
    Futoshi Ishiguro
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    J Surg Res 179:24-32. 2013
  6. doi request reprint Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma
    Keiko Shinjo
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Carcinogenesis 33:1277-85. 2012
  7. doi request reprint Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib
    Kenichi Suda
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    J Thorac Oncol 6:1152-61. 2011
  8. pmc Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis
    Hai xing Ju
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Am J Pathol 178:1835-46. 2011
  9. doi request reprint Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour
    Yasuyuki Okamoto
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Gut 61:392-401. 2012
  10. pmc Contribution of microRNA-1275 to Claudin11 protein suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cells
    Keisuke Katsushima
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
    J Biol Chem 287:27396-406. 2012

Collaborators

Detail Information

Publications15

  1. pmc Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade
    Makiko Fujii
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Cell Cycle 11:3373-9. 2012
    ..Furthermore, we demonstrated the functional importance of CTGF through the mouse studies and human histological analyses, which may elucidate the clinical features of MM with severe fibrosis in the thoracic cavity...
  2. doi request reprint Exploration of a new drug that targets YAP
    Makiko Fujii
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya, Aichi 464 8681, Japan
    J Biochem 152:209-11. 2012
    ..The authors suggest dobutamine as a possible drug for cancer treatment...
  3. pmc TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth
    Makiko Fujii
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Chikusa ku, Nagoya 464 8681, Japan
    J Exp Med 209:479-94. 2012
    ..These data suggest that CTGF is an important modulator of MM growth and pathology and represents a novel therapeutic target for this disease...
  4. doi request reprint Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma
    Futoshi Ishiguro
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    J Thorac Oncol 7:890-9. 2012
    ..However, detailed characteristics of aberrant expression status of cell-adhesion molecules in malignant mesothelioma (MM) cells and their possible biological roles for MM malignancy remain poorly understood...
  5. doi request reprint Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer
    Futoshi Ishiguro
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    J Surg Res 179:24-32. 2013
    ..However, the relationship between ALCAM expression and progression of non-small-cell lung cancer (NSCLC) has not been investigated. This study was designed to clarify the prognostic impact of ALCAM expression of NSCLC cells...
  6. doi request reprint Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma
    Keiko Shinjo
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Carcinogenesis 33:1277-85. 2012
    ..CIMP classification using our six-marker panel has implications for personalized medical strategies for lung cancer patients; in particular, DNA methylation inhibitor might be of therapeutic benefit to patients with CIMP-positive tumors...
  7. doi request reprint Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib
    Kenichi Suda
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    J Thorac Oncol 6:1152-61. 2011
    ..However, recent clinical studies revealed that gefitinib or erlotinib are highly effective in the treatment of non-small cell lung cancer with EGFR mutations...
  8. pmc Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis
    Hai xing Ju
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Am J Pathol 178:1835-46. 2011
    ..In addition, most methylation status in stage IV CRCs seems to be established before metastasis...
  9. doi request reprint Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumour
    Yasuyuki Okamoto
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    Gut 61:392-401. 2012
    ..Our aim was to establish epigenetic profiles associated with the malignant transformation of GISTs...
  10. pmc Contribution of microRNA-1275 to Claudin11 protein suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cells
    Keisuke Katsushima
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
    J Biol Chem 287:27396-406. 2012
    ..Given that inhibition of miR-1275 induces expression of oligodendroglial lineage proteins and suppresses tumor cell proliferation, this may be a potential therapeutic target for glioblastomas...
  11. doi request reprint LATS2 is a tumor suppressor gene of malignant mesothelioma
    Hideki Murakami
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Cancer Res 71:873-83. 2011
    ..Thus, our results suggest that the inactivation of LATS2 is one of the key mechanisms for constitutive activation of YAP, which induces deregulation of MM cell proliferation...
  12. doi request reprint Activation of the PI3K-AKT pathway in human malignant mesothelioma cells
    Yutaro Suzuki
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464 8681, Japan
    Mol Med Report 2:181-8. 2009
    ..These findings suggest that AKT is frequently activated in MM cells, in part due to the downregulation of PTEN. Thus, the PI3K-AKT signaling pathway is a potential therapeutic target for MM...
  13. doi request reprint Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma
    Yasuhiro Goto
    Divisions of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan
    Cancer Res 69:9073-82. 2009
    ..Our findings show a characteristic epigenetic profile of MPM and uncover multiple distinct epigenetic abnormalities that lead to the silencing of tumor suppressor genes in MPM and could serve as diagnostic or prognostic targets...
  14. doi request reprint Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells
    Koji Kawaguchi
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya, Japan
    Carcinogenesis 30:1097-105. 2009
    ....
  15. doi request reprint Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers
    Byonggu An
    Division of Molecular Oncology, Aichi Cancer Center Research Institute, Chikusa ku, Nagoya 464 8681, Japan
    Int J Cancer 127:2095-105. 2010
    ....